Survival Analysis of Breast Cancer in Patients with HER2/neu+, ER-, PR-: a Retrospective Cohort Study-Reference-Cited by-同舟云学术

Survival Analysis of Breast Cancer in Patients with HER2/neu+, ER-, PR-: a Retrospective Cohort Study

Published:2023-09 Issue:3 Volume:12 Page:
ISSN:1758-1923
Container-title:Breast Cancer Management
language:en
Short-container-title:Breast Cancer Manag.

Author:

Babaee Ebrahim¹²^ORCID,Nafissi Nahid³^ORCID,Amani Paria³^ORCID,Hamidabad Negin Mahmoudi³^ORCID,Negahi Alireza³^ORCID,Shojaee Leyla³^ORCID,Tayefi Batool²^ORCID

Affiliation:

1. Vaccine Research Center, Iran University of Medical Sciences, Tehran, Iran

2. Preventive Medicine & Public Health Research Center, Psychosocial Health Research Institute, Community & Family Medicine Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

3. Breast Health & Cancer Research Center, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/bmt-2023-0015

Reference42 articles.

1. Epidemiology and histopathology of breast cancer in Iran versus other middle eastern countries;Nafissi N;Middle. East. J. Cancer,2018

2. Cancer in Iran 2008 to 2025: Recent incidence trends and short‐term predictions of the future burden

3. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

4. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision

5. Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting